[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352575-105":59,"doc-detail-352575-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pmm2-interacts-with-trim28-to-recruit-e2f4-and-promote-kifc3-mediated-tumor-glycolysis-and-colorectal-cancer-progression","PMM2 interacts with TRIM28 to recruit E2F4 and promote KIFC3-mediated tumor glycolysis and colorectal cancer progression","","Colorectal cancer remains a major health burden with limited effective therapies, and new mechanistic targets are urgently needed. This study identifies phosphomannomutase 2 (PMM2) as a key oncogenic driver in CRC. PMM2 is upregulated in CRC tissues and cell lines and associates with advanced stage, lymphatic metastasis, and poor survival. PMM2 knockdown suppresses proliferation, migration, invasion, and glycolysis. Mechanistically, PMM2 recruits E2F4 via TRIM28 nuclear translocation and enhances KIFC3 transcription by promoter binding. KIFC3 loss partially reverses PMM2-driven metabolic reprogramming and tumor growth, including in patient-derived organoids. These findings position PMM2 as a prognostic biomarker and potential therapeutic target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pmm2-interacts-with-trim28-to-recruit-e2f4-and-promote-kifc3-mediated-tumor-glycolysis-and-colorectal-cancer-progression/352575/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pmm2-interacts-with-trim28-to-recruit-e2f4-and-promote-kifc3-mediated-tumor-glycolysis-and-colorectal-cancer-progression/352575.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does PMM2 play in colorectal cancer progression?","Question",{"text":112,"@type":113},"PMM2 is identified as a key oncogenic driver. Its upregulation correlates with advanced tumor stages, lymphatic metastasis, and poor patient survival, and PMM2 knockdown suppresses CRC malignant behaviors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does PMM2 regulate glycolysis and tumor growth mechanistically?",{"text":117,"@type":113},"PMM2 interacts with transcriptional regulator TRIM28 to promote TRIM28 nuclear translocation, recruit E2F4, and enhance KIFC3 transcription by binding to its promoter. KIFC3 then mediates PMM2-driven glycolysis and supports tumor growth.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the PMM2–KIFC3 axis in CRC?",{"text":121,"@type":113},"Functional assays show that KIFC3 knockdown partially reverses PMM2-induced metabolic reprogramming and tumor growth in xenograft models. Patient-derived organoid studies further confirm PMM2’s role in promoting CRC progression through the PMM2–KIFC3 axis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352575,1791044105,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nARTICLE OPEN   \nPMM2 interacts with TRIM28 to recruit E2F4 and promote KIFC3-mediated tumor glycolysis and colorectal cancer progression  \nZheng Peng1,5, Bing Ma1,5, Zhou Song 1,5, Yunshan Zhao2, Yang Yang2, Yong Liu3, Chenggang Li 4 ✉ and Yong Zhang 1 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Colorectal cancer (CRC) remains a major global health burden with limited therapeutic options. This study identiﬁesphosphomannomutase 2 (PMM2) as a key oncogenic driver in CRC. PMM2 is signiﬁcantly upregulated in CRC tissues and cell lines, correlating with advanced tumor stages, lymphatic metastasis, and poor patient survival. Functional assays reveal that PMM2 knockdown inhibits CRC cell proliferation, migration, invasion, and glycolytic activity (reducing glucose uptake, ATP/lactate production, and extracellular acidiﬁcation rate) . Mechanistically, PMM2 interacts with transcriptional regulator TRIM28, promoting TRIM28 nuclear translocation, recruiting transcription factor E2F4, and enhancing KIFC3 transcription by binding to its promoter. KIFC3 mediates PMM2-driven glycolysis, as KIFC3 knockdown partially reverses PMM2-induced metabolic reprogramming and tumor growth in xenograft models. Patient-derived organoid studies further conﬁrm PMM2’s role in promoting CRC progression through the PMM2-KIFC3 axis. Collectively, these ﬁndings establish PMM2 as a prognostic biomarker and potential therapeutic |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| target in CRC, highlighting its critical role in metabolic reprogramming and tumorigenesis. |  |  |\n|  | Oncogene (2026) 45:1145–1160; [https://doi.org/10.1038/s41388-026-03707-x](https://doi.org/10.1038/s41388-026-03707-x) |  |\n|  |  |  |\n\nINTRODUCTION  \nColorectal cancer (CRC), one of the most prevalent malignancies of the digestive system, arises from epithelial cells in the colon or rectum due to cumulative genetic and environmental perturbations, progressing from adenomatous polyps to invasive carcinoma [1] . Epidemiologically, CRC ranks as the third most incident cancer globally (10.0% incidence rate) and the second leading cause of cancer-related mortality (8.8%), with developing regions like China experiencing rising incidence rates despite declining trends in developed nations [2] . Current diagnostic modalities, including colonoscopy and histopathological evaluation, remain foundational, while therapeutic strategies—surgical resection, chemotherapy, and radiotherapy—show limited efﬁcacy in advanced or metastatic stages [3] . Targeted therapies (e.g., antiEGFR/cetuximab, anti-VEGF/bevacizumab) and immunotherapies have emerged as adjuncts, yet their applicability is restricted to \u003C15% of metastatic CRC patients due to primary or acquired resistance [4, 5] . Prognostic biomarkers such as microsatellite instability (MSI) and mutations in KRAS, NRAS, and BRAF offer partial guidance but fail to address the unmet need for novel therapeutic targets and mechanistic insights [6, 7] . Thus, elucidating CRC pathogenesis and its molecular regulatory networks remains critical to overcoming treatment stagnation.  \nPhosphomannomutase 2 (PMM2), encoded by the PMM2 gene on chromosome 16p13, catalyzes the conversion of mannose-6-phosphate (Man-6-P) to mannose-1-phosphate (Man-1-P), a  \npivotal step in glycosylation—the enzymatic attachment of oligosaccharides to proteins or lipids to form functional glycoconjugates [8, 9] . Dysregulation of this pathway underlies PMM2-CDG (Congenital Disorder of Glycosylation type Ia), a severe multisystem disorder characterized by early mortality due to neuronal and hepatic dysfunction [9–11] . In cancer, PMM2 exhibits importantly roles. The accumulation of studies reveal PMM2 upregulation in breast [12, 13], renal [14], and cervical cancers [15], where it correlates with tumor aggressiveness and therapeutic resistance. In addition, PMM2 overexpressio","cbCaif3p9W5XciFq","https://ap.wps.com/l/cbCaif3p9W5XciFq","pdf",7186240,16,"English","# Introduction\n## Background on colorectal cancer burden and treatment limitations\n## PMM2 biology and known roles in glycosylation and cancer\n## Study rationale and objective","[{\"question\":\"What role does PMM2 play in colorectal cancer progression?\",\"answer\":\"PMM2 is identified as a key oncogenic driver. Its upregulation correlates with advanced tumor stages, lymphatic metastasis, and poor patient survival, and PMM2 knockdown suppresses CRC malignant behaviors.\"},{\"question\":\"How does PMM2 regulate glycolysis and tumor growth mechanistically?\",\"answer\":\"PMM2 interacts with transcriptional regulator TRIM28 to promote TRIM28 nuclear translocation, recruit E2F4, and enhance KIFC3 transcription by binding to its promoter. KIFC3 then mediates PMM2-driven glycolysis and supports tumor growth.\"},{\"question\":\"What evidence supports the PMM2–KIFC3 axis in CRC?\",\"answer\":\"Functional assays show that KIFC3 knockdown partially reverses PMM2-induced metabolic reprogramming and tumor growth in xenograft models. Patient-derived organoid studies further confirm PMM2’s role in promoting CRC progression through the PMM2–KIFC3 axis.\"}]","PMM2 interacts with TRIM28 to recruit E2F4 and promote KIFC3-mediated tumor glycolysis and colorectal cancer progression | PDF",1790100321,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28df55cf3f32acbdf509050b15ceec36.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf53b856adf22720ea30244fd393ba00.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51b32d9cb44862995c59f99614df5d30.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca5310bec99930b749b8ce3ac919ebb9.webp",980,1301]